Literature DB >> 2379536

Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man.

S M Carlsson1, T Denneberg, B M Emanuelsson, B Kågedal, S Lindgren.   

Abstract

The pharmacokinetics of 2-mercaptopropionylglycine (2-MPG) was studied in ten healthy volunteers after a single i.v. injection of 250 mg (1532 mumol). The total and non-protein-bound concentrations versus time curves were best described by a three-exponential function with terminal half-lives of 55 and 59 h respectively. Body clearance based upon the total concentration was estimated to be 105 and 231 ml/min based on the non-protein-bound 2-MPG. The corresponding values for Vss were 99 l and Vss,n 173 l, and for V gamma 485 l and V gamma,n 1121 l respectively. 75% of the dose was excreted in the urine, mainly during the first 6 h after injection. The proportion of non-protein-bound 2-MPG diminished exponentially during the first 15 h and then levelled off at about 30%. There was a nonlinear increase in the non-protein-bound fraction of 2-MPG as the total plasma concentration of the drug increased.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379536     DOI: 10.1007/bf02336691

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Effect of penicillamine on cystinuria.

Authors:  J C CRAWHALL; E F SCOWEN; R W WATTS
Journal:  Br Med J       Date:  1963-03-02

3.  Treatment of cystinuria with Thiola (alpha-mercaptopropionyl glycine).

Authors:  A Remien; G Kallistratos; P Burchardt
Journal:  Eur Urol       Date:  1975       Impact factor: 20.096

Review 4.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

5.  Determination of 2-mercaptopropionylglycine in plasma and urine by high-performance liquid chromatography.

Authors:  B Kågedal; M Carlsson; T Denneberg
Journal:  J Chromatogr       Date:  1986-08-02

6.  Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine.

Authors:  C Y Pak; C Fuller; K Sakhaee; J E Zerwekh; B V Adams
Journal:  J Urol       Date:  1986-11       Impact factor: 7.450

7.  High-performance liquid chromatography of 2-mercaptopropionylglycine and its metabolite 2-mercaptopropionic acid in plasma and urine after treatment with thiopronine.

Authors:  B Kågedal; T Andersson; M Carlsson; T Denneberg; A Hoppe
Journal:  J Chromatogr       Date:  1987-07-03

Review 8.  Adverse effects profile of sulfhydryl compounds in man.

Authors:  I A Jaffe
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

9.  Alternative treatment of cystinuria with alpha-merkaptopropionylglycine, Thiola.

Authors:  T Denneberg; J O Jeppsson; P Stenberg
Journal:  Proc Eur Dial Transplant Assoc       Date:  1983

10.  The use of D-penicillamine in cystinuria: efficacy and untoward reactions.

Authors:  E C Halperin; S O Thier; L E Rosenberg
Journal:  Yale J Biol Med       Date:  1981 Nov-Dec
View more
  5 in total

1.  Changes in clearance create pharmacokinetic pitfalls as illustrated by studies on tiopronin.

Authors:  P A Sjöström
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

2.  The pharmacokinetics of tiopronin as such is unknown.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Pharmacokinetics of oral tiopronin.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury.

Authors:  H Suzuki; A Matsumori; Y Matoba; B S Kyu; A Tanaka; J Fujita; S Sasayama
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

5.  The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers.

Authors:  B Hercelin; P Leroy; A Nicolas; C Gavriloff; D Chassard; J J Thébault; M T Reveillaud; M F Salles; P Netter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.